Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Wet Age-related Macular Degeneration (Wet AMD)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT00414206
What this trial is testing

Safety and Efficacy of ATG003 in Patients With Wet Age-Related Macular Degeneration (AMD)

Who this might be right for
Macular Degeneration
CoMentis 343
Post-approval studies (Phase 4)Study completedNCT04774926
What this trial is testing

Study of Innovative Multimodal Imaging Biomarkers to Predict Anatomical Outcome in Naive Patients With wAMD Treated With Brolucizumab.

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 122
Testing effectiveness (Phase 2)Active Not RecruitingNCT05984927
What this trial is testing

NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration

Who this might be right for
Age-Related Macular Degeneration
Elisigen, Inc. 20
Testing effectiveness (Phase 2)Study completedNCT02121522
What this trial is testing

A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration

Who this might be right for
Wet Macular Degeneration
Boehringer Ingelheim 14
Not applicableActive Not RecruitingNCT04932980
What this trial is testing

Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD

Who this might be right for
Wet Age-related Macular Degeneration
Berner Augenklinik 80
Early research (Phase 1)WithdrawnNCT04919096
What this trial is testing

Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration

Who this might be right for
Wet Age-related Macular Degeneration
Clover Biopharmaceuticals AUS Pty
Post-approval studies (Phase 4)Study completedNCT01006538
What this trial is testing

Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT)

Who this might be right for
Macular Degeneration
King's College Hospital NHS Trust 363
Testing effectiveness (Phase 2)Study completedNCT01972763
What this trial is testing

Ranibizumab for Recalcitrant Wet Age-related Macular Degeneration in Eyes Previously Switched From Bevacizumab and/or Ranibizumab to Aflibercept.

Who this might be right for
Recalcitrant Wet Age-related Macular Degeneration
Northern California Retina Vitreous Associates 12
Large-scale testing (Phase 3)Active Not RecruitingNCT06668064
What this trial is testing

A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56

Who this might be right for
Wet Age Related Macular DegenerationwAMD
EyePoint Pharmaceuticals, Inc. 400
Not applicableUnknownNCT02988895
What this trial is testing

Episcleral Brachytherapy for the Treatment of Wet AMD

Who this might be right for
Macular Degeneration, Choroidal Neovascularization
Salutaris Medical Devices, Inc. 11
Large-scale testing (Phase 3)Not Yet RecruitingNCT07129239
What this trial is testing

High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)

Who this might be right for
Wet Age-related Macular Degeneration (wAMD)
Clinique de Retine de l'est 180
Post-approval studies (Phase 4)Study completedNCT02689518
What this trial is testing

EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection

Who this might be right for
Macular DegenerationWet Macular Degeneration
University of California, San Diego 50
Testing effectiveness (Phase 2)Study completedNCT03953079
What this trial is testing

A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD

Who this might be right for
Neovascular Age-Related Macular Degeneration
Graybug Vision 56
Not applicableStudy completedNCT00656903
What this trial is testing

High Speed Indocyanine Green Angiography Findings in Ranibizumab Treatment for Wet Age-related Macular Degeneration

Who this might be right for
Macular Degeneration
National Eye Institute (NEI) 75
Large-scale testing (Phase 3)Study completedNCT04516278
What this trial is testing

A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders

Who this might be right for
Age-related Macular DegenerationNeovascular Age-related Macular DegenerationWet Macular Degeneration+2 more
Outlook Therapeutics, Inc. 197
Not applicableStudy completedNCT07255885
What this trial is testing

CRYSTALSIGHT: ''Cohort 1.5" Clinical Investigation Study With OCCUTRACK and Tan Tock Seng Eye Clinic to Further Develop Remote Monitoring of Maculopathy at Home Using Artificial Intelligence for Eye Tracking

Who this might be right for
MaculopathyMaculopathy, Age RelatedMacular Degeneration, Age-Related+3 more
Tan Tock Seng Hospital 20
Testing effectiveness (Phase 2)Study completedNCT06176963
What this trial is testing

Evaluate the Usability of the SB11 PFS in Subjects With Wet AMD or Macular Oedema Secondary to RVO

Who this might be right for
Neovascular Age-related Macular DegenerationMacular EdemaRetinal Vein Occlusion
Samsung Bioepis Co., Ltd. 34
Large-scale testing (Phase 3)Study completedNCT03677934
What this trial is testing

A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration

Who this might be right for
Neovascular Age-Related Macular Degeneration
Hoffmann-La Roche 415
Large-scale testing (Phase 3)Study completedNCT04597632
What this trial is testing

An Extension Study Assessing the Efficacy and Safety of Brolucizumab in a Treat-to-Control Regimen in Patients With Neovascular Age-related Macular Degeneration Who Have Completed the CRTH258A2303 (TALON) Study

Who this might be right for
Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals 248
Testing effectiveness (Phase 2)Looking for participantsNCT07547228
What this trial is testing

PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)

Who this might be right for
Neovascular Age Related Macular Degeneration
Intra-IMMUSG Pte Ltd 15
Next Page